Ferrannini, E., Berk, A., Hantel, S., Pinnetti, S., Hach, T., Woerle, H. J., & Broedl, U. C. (2013). Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. American Diabetes Association.

Ferrannini, Ele, Andreas Berk, Stefan Hantel, Sabine Pinnetti, Thomas Hach, Hans J. Woerle, and Uli C. Broedl. Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An Active-controlled, Parallel-group, Randomized, 78-week Open-label Extension Study in Patients With Type 2 Diabetes. American Diabetes Association, 2013.

Ferrannini, Ele, et al. Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An Active-controlled, Parallel-group, Randomized, 78-week Open-label Extension Study in Patients With Type 2 Diabetes. American Diabetes Association, 2013.